Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norihiro Watanabe

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic CancerSomala Mohammed, Sujita Sukumaran, Pradip Bajgain, et al.
Journal for Immunotherapy of Cancer|January 18, 2023
Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stromaMary K McKenna, Ada Ozcan, Daniel Brenner, et al.
Nature Communications|February 4, 2026
Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptorChiou-Tsun Tsai, Jorge Ibanez-Vega, Pan Yin, et al.
Medical Oncology (Northwood, London, England)|December 6, 2008
Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNAMiwako Narita, Nozomi Tochiki, Anri Saitoh, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 16, 2014
Reversal of tumor immune inhibition using a chimeric cytokine receptorAnn M Leen, Sujita Sukumaran, Norihiro Watanabe, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancerSaisha A Nalawade, Paul Shafer, Pradip Bajgain, et al.
Plos One|August 18, 2012
Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALSAtsushi Shiga, Tomohiko Ishihara, Akinori Miyashita, et al.
International Journal of Medical Sciences|April 30, 2010
WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phaseMiwako Narita, Masayoshi Masuko, Tohri Kurasaki, et al.
Blood|January 19, 2024
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemiaWingchi K Leung, Alejandro G Torres Chavez, Matthew French-Kim, et al.
Blood|August 31, 2022
Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantationFeiyan Mo, Norihiro Watanabe, Kayleigh I Omdahl, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic CancerSomala Mohammed, Sujita Sukumaran, Pradip Bajgain, et al.
Journal for Immunotherapy of Cancer|January 18, 2023
Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stromaMary K McKenna, Ada Ozcan, Daniel Brenner, et al.
Nature Communications|February 4, 2026
Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptorChiou-Tsun Tsai, Jorge Ibanez-Vega, Pan Yin, et al.
Medical Oncology (Northwood, London, England)|December 6, 2008
Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNAMiwako Narita, Nozomi Tochiki, Anri Saitoh, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 16, 2014
Reversal of tumor immune inhibition using a chimeric cytokine receptorAnn M Leen, Sujita Sukumaran, Norihiro Watanabe, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancerSaisha A Nalawade, Paul Shafer, Pradip Bajgain, et al.
Plos One|August 18, 2012
Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALSAtsushi Shiga, Tomohiko Ishihara, Akinori Miyashita, et al.
International Journal of Medical Sciences|April 30, 2010
WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phaseMiwako Narita, Masayoshi Masuko, Tohri Kurasaki, et al.
Blood|January 19, 2024
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemiaWingchi K Leung, Alejandro G Torres Chavez, Matthew French-Kim, et al.
Blood|August 31, 2022
Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantationFeiyan Mo, Norihiro Watanabe, Kayleigh I Omdahl, et al.
Pageof 5